U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Drug Approvals and Databases
  5. Drug Trials Snapshots: DETECTNET
  1. Drug Approvals and Databases

Drug Trials Snapshots: DETECTNET

The information provided in Snapshots highlights who participated in the clinical trials that supported the FDA approval of this drug, and whether there were differences among sex, race and age groups. The “MORE INFO” bar shows more detailed, technical content for each section. The Snapshot is intended as one tool for consumers to use when discussing the risks and benefits of the drugs.

Do not rely on Snapshots to make decisions regarding medical care. Always speak to your health provider about the risks and benefits of a drug. Refer to the DETECTNET Prescribing Information for complete information.

DETECTNET (copper Cu 64 dotatate)
RadioMedix, Inc.
Approval date: September 3, 2020


What is the drug for?

DETECTNET is a drug for detection of the specific type of tumors called somatostatin receptor positive neuro-endocrine tumors (NETs) in adults.

NETs are rare tumors that develop in certain hormone-producing cells of the body’s neuro-endocrine system.

How is this drug used?

DETECTNET is injected into a vein in preparation for an imaging test (called positron emission tomography scan or PET scan) to help detect the tumor.

What are the benefits of this drug?

enter text

Were there any differences in how well the drug worked in clinical trials among sex, race and age?

  • Sex: DETECTNET worked similarly in men and women.
  • Race: The majority of patients were White. The number of patients of other races were limited; therefore, differences in how the drug worked among races could not be determined.
  • Age: DETECTNET worked similarly in patients younger and older than 60 years of age.

What are the possible side effects?

DETECTNET is a radioactive drug which may increase the risk of lifetime radiation exposure.

The most common side effects of DETECTNET are nausea, vomiting, and flushing.

Were there any differences in side effects among sex, race and age?

Because the side effects were rare, it was not possible to determine the differences in side effects among sex, race and age.


Who participated in the trials?

The FDA approved DETECTNET based on data from two trials that evaluated 175 adult patients.

Trial 1 evaluated adult patients, some of whom had known or suspected NETs and some of whom were healthy volunteers. The trial was conducted at one site in the United States (Houston, TX).

Trial 2 data came from the literature-reported trial of 112 adult patients, all of whom had history of NETs. The trial was conducted at one site in Denmark.

The figure below summarizes how many men and women were in the clinical trials.

Figure 1. Demographics by Sex

Pie chart summarizing how many men and women were in the clinical trial. In total, 84 women (48%) and 91 men (52%) participated in the clinical trial.

Adapted from FDA Review

The figure below summarizes patients in the clinical trials by race.

Figure 2. Demographics by Race

Pie chart summarizing the percentage of patients by race enrolled in the clinical trial. In total, 54 White (31%), 6 Black or African American  (3%), 3 Asian (2%) and 112 (64%) Not Reported.

Adapted from FDA Review

The figure below summarizes patients in the clinical trials by age.

Figure 3. Demographics by Age

Pie charts summarizing how many individuals of certain age groups were enrolled in the clinical trial. In total,  109 (62%) were less than 65 and 66 patients were 65 years and older (38%).

Adapted from FDA Review

The figure below summarizes patients in the clinical trials by ethnicity.

Figure 3. Demographics by Ethnicity

Pie charts summarizing ethnicity of patients enrolled in the clinical trial. In total,  11 patients were Hispanic or Latino (6%) and 52 patients were not Hispanic or Latino (30%).

Adapted from FDA Review

How were the trials designed?

For DETECTNET approval, the FDA evaluated the data from two trials.

In Trial 1, some patients had NETs, and some did not. Both groups received DETECTNET and underwent PET scan imaging.

In Trial 2, all patients had history of NETs and underwent PET scan imaging with DETECTNET.

In both trials, DETECTNET images were compared to either biopsy results or other images taken by different techniques to detect the sites of a tumor. The images were read as either positive or negative for presence of NETs by three independent image readers who did not know patient clinical information.


CLINICAL TRIAL: Voluntary research studies conducted in people and designed to answer specific questions about the safety or effectiveness of drugs, vaccines, other therapies, or new ways of using existing treatments.
COMPARATOR: A previously available treatment or placebo used in clinical trials that is compared to the actual drug being tested.
EFFICACY: How well the drug achieves the desired response when it is taken as described in a controlled clinical setting, such as during a clinical trial.
PLACEBO: An inactive substance or “sugar pill” that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.
SUBGROUP: A subset of the population studied in a clinical trial. Demographic subsets include sex, race, and age groups.


Back to Drug Trials Snapshots


Back to Top